Laboratory surveillance of dengue fever in New-Caledonia

Similar documents
Chikungunya outbreak in New Caledonia in 2011 Status report as at 22 August 2011

COMPARISON OF PANBIO DENGUE IGM ELISA ASSAY WITH PENTAX DENGUE IGM PARTICLE AGGLUTINATION ASSAY TO EVALUATE FACTORS AFFECTING FALSE POSITIVE RESULTS

Narendra Singh * Tom Kiedrzynski ** Christelle Lepers *** Elise Kamisan Benyon ****

World Health Organization, Western Pacific Regional Office, Manila, Philippines Issue 13 September 2007 ISSN

BULLETIN. World Health Organization, Western Pacific Regional Office, Manila, Philippines Issue 11 December 2006 ISSN

Update on the Dengue situation in the Western Pacific Region


Institut Pasteur de Nouvelle Calédonie 12 / 12 / 02

Dengue, an emerging arboviral infection, continues

BULLETIN. World Health Organization, Western Pacific Regional Office, Manila, Philippines Issue 8 January 2006 ISSN

Dengue Situation Update Number 534. Update on the Dengue situation in the Western Pacific Region

Syndromic surveillance in French Polynesia

Inform'ACTION n 25 DECEMBER 2006

Update on the Dengue situation in the Western Pacific Region

Update on the Dengue situation in the Western Pacific Region

Update on the Dengue situation in the Western Pacific Region

Evaluation of a New Anti-Dengue Virus IgM Particle Agglutination Kit in the Context of the Pacific Islands

Update on seasonal influenza in the Southern Hemisphere in

In recent years, dengue has become a major public

French Pacific territories workshop. Conclusions and recommendations

Ministry of Health and Medical Services Solomon Islands. Dengue Outbreak: External Sitrep No. 3. From Epidemiological Week 33-41, 2016

REVIEW OF TUBERCULOSIS EPIDEMIOLOGY

Dengue Situation Update Number Update on the Dengue situation in the Western Pacific Region

TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report

Update on the Dengue situation in the Western Pacific Region

Citation 熱帯医学 Tropical medicine 35(4). p147-

History and particular features of dengue epidemiology in French Polynesia

Update on the Dengue situation in the Western Pacific Region

Update on the Dengue situation in the Western Pacific Region

BULLETIN. World Health Organization, Western Pacific Regional Office, Manila, Philippines Issue 10 August 2006 ISSN


Dengue Situation Update Number Update on the Dengue situation in the Western Pacific Region

Bi-weekly Influenza Situation Update

Dengue Situation Update Number 450. Update on the dengue situation in the Western Pacific Region

Bi-weekly Influenza Situation Update

Influenza treatment centres in New Caledonia

Update on the Dengue situation in the Western Pacific Region

Update on the dengue situation in the Western Pacific Region

Influenza surveillance summary

Influenza Situation Update

*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a

Action Plan to Reduce the Double Burden of Malnutrition in the Western Pacific Region. Dr Katrin Engelhardt, MPH Technical Lead, Nutrition DNH/WPRO

Western Pacific Regional Office of the World Health Organization WPRO Dengue Situation Update, 2 October 2013 Recent Cumulative No.

Western Pacific Region Neglected Tropical Diseases News

Dengue Situa0on Update Number 521. Update on the Dengue situa0on in the Western Pacific Region

Overview of pandemic preparedness

WHO priorities for 2016 in US PICTs

Influenza Situation Update

Evaluating reagents for serological diagnosis of Leptospirosis EPINET 1 Workshop (Guam, December 2001)

Minnesota Influenza Geographic Spread

Minnesota Influenza Geographic Spread

Minnesota Influenza Geographic Spread

Weekly Influenza & Respiratory Illness Activity Report

Zika Virus Update for Emergency Care Providers

Eurosurveillance 2006;11 (2):

Minnesota Influenza Geographic Spread

Minnesota Influenza Geographic Spread

Highlights. NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE Influenza Surveillance Report Week ending January 28, 2017 (Week 4)

Influenza Surveillance Report

Minnesota Influenza Geographic Spread

Bi-weekly Influenza Situation Update

Figure 1. Incidence rate of total (confirmed and compatible) measles cases with rash onset 1 31 December 2017, WHO Western Pacific Region

Minnesota Influenza Geographic Spread

TUBERCULOSIS CONTROL WHO WESTERN PACIFIC REGION

Minnesota Influenza Geographic Spread

Weekly Influenza Surveillance Report. Week 11

2009 Report. Tuberculosis Control. in the Western Pacific Region

Figure 1. Distribution of confirmed measles cases with rash onset 1 30 September 2014, WHO Western Pacific Region

Zika Virus in the Primary Care Setting

Everything you ever wanted to know about Zika Virus Disease

Ministry of Health and Medical Services Solomon Islands. Dengue Outbreak: External Sitrep No. 8

2006 Report. Tuberculosis Control. in the Western Pacific Region

Weekly Influenza & Respiratory Illness Activity Report

Influenza Situation Update

The Role of Medical Devices to Improve Health Service Delivery

Downloaded from:

Meeting Report. 29 September to 1 October 2015 Nadi, Fiji

Guide on Access to the Yellow Fever ICG Stockpile. Emergency Campaigns. International Coordinating Group on Vaccine. Geneva, Switzerland 2012

Epidemiology and entomology of the Zika virus outbreak

Watery diarrhea. Non-watery diarrhea

Nova Scotia s Response to H1N1. Summary Report

SITUATION REPORT YELLOW FEVER 16 JUNE 2016 SUMMARY

Date of report: 08/05/2014 (Tuesday) for cases presenting on: 08/02/2014 and 08/03/2014 (Saturday and Sunday)

Figure 1. Distribution of confirmed measles cases with rash onset 1 31 August 2014, WHO Western Pacific Region

Figure 1. Incidence rate of total (confirmed and compatible) measles cases with rash onset 1 31 March 2018, WHO Western Pacific Region

Ohio Department of Health Seasonal Influenza Activity Summary MMWR Week 14 April 3 9, 2011

Figure 1. Incidence rate of total (confirmed and compatible) measles cases with rash onset 1 31 December 2018, WHO Western Pacific Region

What s Lurking out there??????

IMMUNISATION CHALLENGES IN FIJI AND THE PACIFIC. 10th New Zealand Immunization Conference Litiana Volavola, National EPI Programme Officer, Fiji

AN UPDATE ON REGIONAL STATISTICS ACTIVITIES AND PARTNERSHIP PROGRAM - Paper 4

Economic Consequences of an Infectious Disease Event for a Small, Island Economy

Figure 1. Distribution of confirmed measles cases with rash onset 1 31 December 2014, WHO Western Pacific Region

Public Health Image Library. CDC/ Cynthia Goldsmith. Image #

MONTHLY NOTIFIABLE DISEASE SURVEILLANCE REPORT

Bi-weekly Influenza Situation Update

6. SURVEILLANCE AND OUTRBREAK RESPONSE

Leptospirosis as a public health concern New Caledonia as a case study

Diarrhoeal disease outbreak investigation in Guadalcanal and Honiara Provinces, September November 2008

Transcription:

Laboratory surveillance of dengue fever in New-Caledonia - 24 I. Introduction After a period of calm in 1999 and 2, the risk of renewed outbreaks in New Caledonia rose to a higher level in 21 due to an increasing number of DEN 1 foci in the Pacific, particularly in French Polynesia, where more than 33, people were affected in 21, and then in Wallis and Futuna in 22-3. After numerous imported cases in 22, this threat became a reality in New Caledonia in 23 with a major epidemic, probably one of the biggest the Territory has ever known. In 24, moderate transmission of the virus recommenced then most probably halted at the end of the cool season. Laboratory surveillance of dengue fever is conducted by the virology laboratory at the New Caledonia Pasteur Institute (IPNC). This surveillance combines an active component covered by the Sentinel Network with response to lab test requests received from outside the Network. II. Sentinel Network in 24 Composition: For the most part, the initial composition of the Sentinel Network remained the same as in previous years, i.e. 23 public or private centres spread throughout the three s in such a way as to ensure proper geographic and socio-economic coverage. All the Provincial health care centres continued to be part of the network so as to identify any possible re-emerging foci after the 23 epidemic as quickly as possible. Operating procedure: When a sentinel physician comes across a clinically suspect case, he or she fills out an information sheet and orders a set of lab tests to confirm the case. The disease-specific tests are covered 1% by the public health subvention funding New Caledonia has provided to the Pasteur Institute. Other analyses prescribed at the same time, e.g. platelet count/composition, are paid by the patient and can be reimbursed at normal health coverage rates. The laboratory decides on the exact diagnostic parameters depending on the start date given for the illness. With early samples (D1 to D6 from when the fever first appears), the lab looks for viral RNA using a molecular biology technique that makes it possible to identify the viral type (PCR : Polymerase Chain Reaction). On late samples (after D6), specific IgM detection is carried using an ELISA method. Positive cases are declared probable (positive results for IgM from a single sample) or confirmed (positive PCR or seroconversion found in two successive samples). Suspected cases (test requested) and then positive cases are reported as soon as they are available to the prescribing physician and the DASS-NC (New Caledonia Department of Health and Social Affairs) for immediate implementation of vector control measures and for epidemiological purposes. Depending on how the epidemiological situation evolves, the Pasteur Institute produces periodical surveillance reports, sent by fax or e-mail to sentinel sites and the DASS (5 reports in 24). 1

III. Results and analysis Overall laboratory results: Laboratory surveillance of dengue fever, 24 Origin New Caledonia Wallis and Futuna Total Recruited by the Sentinel Network Number of patients tested by the laboratory Patients that had repeated samples taken (2 or more) Declared positive (IgM or PCR +) 2563 531 (2.76%) 14 (4%) 46 (17.9%) 73 - - 17 (23.3%) Region * 92 - - 45 (48.9%) * : samples received from Palau, Vanuatu, Guam, Chuuk and Yap. The number of patients diagnosed in 24 was only 2% of the number of declared cases in 23, and, in a similar way, the sample positivity rate dropped some 5% (34.4% in 23). These two indicators clearly describe a post-epidemic year with residual transmission of the virus. Through the IPNC s activities within the Pacific Public Health Surveillance Network (PPHSN), the Institute contributed to identification of the most recent region focus in Micronesia (June-October 24). Chronology of positive cases: Weekly surveillance of dengue fever (NC 24) 14 5.% Number of patients tested 12 1 8 6 4 2 45.% 4.% 35.% 3.% 25.% 2.% 15.% 1.% 5.% % of confirmed patients 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 Week.% Patients testés Cas confirmés Taux de confirmation hebdomadaire Taux de confirmation (tendance) Patients tested Confirmed cases Weekly confirmation rate Confirmation rate (trend) Most cases were identified between January and July 24, with a slight peak in March. From August onwards, the weekly confirmation rate dropped, thereby showing a probable halt in transmission. In addition, this situation was validated by a lack of cases confirmed through PCR after late July. 2

Geographic origin of the patients tested by the laboratory and declared positive for dengue fever: Northern 41 cases Municipal district (commune) Confirmed cases in 24 Municipal district (commune) Confirmed cases in 24 Belep 1 Boulouparis 5 Canala 2 Bourail 8 Hienghene 3 Dumbéa 37 Houailou 3 Farino Kaala Gomen Isle of Pines Kone 14 Southern La Foa 5 Kouaoua 1 359 Moindou Koumac cases Mont Dore 43 Népoui Noumea 238 Ouégoa Paita 2 Poindimié 3 Sarraméa Ponerihouen 2 Thio Pouébo Yaté 3 Pouembout 1 Loyalty Island Lifou 11 Poum Maré 28 45 Poya 1 cases Ouvéa 6 Touho 1 Unknown origin 15 Voh 9 Total 46 Some 22 of the 33 municipal districts (communes) in New Caledonia declared at least one laboratory confirmed case in 24. Effective transmission was probably only maintained over the first six months of the year in the greater Noumea area and, in clearly smaller percentages, in the Kone-Voh region and on Mare in April-May. Demographic characteristics of dengue-positive patients: Distribution by sex: The distribution of positive cases by sex did not show any predominance: Sex Number of cases Distribution Male 219 47.6% Female 241 52.4% Age of patients: The mean was situated at 34.6 years of age but showed extreme dispersion going from 1 month to 88 years of age. As in 23, the confirmation rate by age group, given below, did not show any significant variations. Type 1 dengue fever had probably only been transmitted at fairly low levels between 1975 and 1978, then as a moderate outbreak in 1989-9 (the outbreak over those two years was mainly due to the Type 3 virus). Given the time span since these periods of transmission of the same virus type, no immunological protection could be shown for the age categories involved. 3

Distribution of dengue fever cases by age group (NC 24) 3 5.% 45.% Number of patients 25 2 15 1 5 4.% 35.% 3.% 25.% 2.% 15.% 1.% 5.%.% à 5 ans 5 à 1 ans 1 à 15 ans 15 à 2 ans 2 à 25 ans 25 à 3 ans 3 à 35 ans 35 à 4 ans 4 à 45 ans 45 à 5 ans 5 à 55 ans 55 à 6 ans 6 à 65 ans 65 à 7 ans 7 à 75 ans 75 à 8 ans 8 à 85 ans 85 à 9 ans 9 à 95 ans 95 à 1 ans % of confirmed cases by age group Age groups Confirmés Testés % confirmés par groupe d'age % confirmés par groupes d'ages (tendance) Confirmed Tested % confirmed by age group % confirmed by age group (trend) Virological data : The 46 cases that had positive dengue-specific tests results were distributed as follows: - Cases confirmed by identification of DEN 1 viral RNA: 179 - Probable cases due to the presence of IgM: 281 After late July, no further cases were confirmed through viral genome identification. It is likely that most of the so-called probable cases identified from positive IgM results did not correspond to infections at the time of testing. They probably involved IgM persisting some time after the illness or unspecified reactivity linked to polyclonal activation as part of another acute infection process. 4

4 Weekly changes in case confirmation mode (Dengue 1, NC 24) 1 Number of cases 35 3 25 2 15 1 5.8.6.4.2 -.2 Percentage of cases confirmed by PCR 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 Week -.4 IgM + PCR DEN 1 + Proportion de PCR Proportion de PCR (tendance) IgM + PCR DEN 1+ Percentage of PCR Percentage of PCR (trend) Mortality : As at 31/12/24, two reports of deaths that occurred in a dengue fever context had been recorded by the DASS-NC. IV. Conclusion From 21 onwards, New Caledonia was exposed to a high risk of a DEN 1 outbreak from neighbouring countries and territories, in particular, French Polynesia and Wallis & Futuna, with which there are frequent, large-scale exchanges of population. In the Pacific region, transmission of the Type 1 virus began in late 2, when it was first reported in Palau. A major epidemic then took place in French Polynesia from February to November 21. It began on Bora-Bora then gradually spread to most of the island group. After that other foci were reported in Samoa, Tokelau, the Cook Islands and then Hawaii. In early 22, cases were reported in the Solomon Islands, then in Vanuatu and in New Caledonia. In late 22, there was an outbreak in Wallis and Futuna. Finally, in 23, a very intense outbreak occurred in New Caledonia that also affected Tonga and then Fiji. Things were calmer in 24, which was characterized by the gradual disappearance of foci. A single case of reemergence, that lasted only a few weeks, took place in Micronesia (states of Yap and Chuuk). The Sentinel Network s role in 24 was to identify as quickly as possible initial reactivated foci at the beginning of the hot season. This moderate-level transmission only continued unbroken in the greater Noumea area until the month of July, and then most likely ended at the close of the cool season. In early 25, there are no signs of the outbreak reoccurring. Endemisation of the virus in the Territory has probably been avoided but this needs to be confirmed by on-going surveillance, at the very least through surveillance network activity Alain BERLIOZ-ARTHAUD IPNC, Centre de Biologie Médicale 9-11, avenue Paul Doumer BP 61-98845 Nouméa Cedex Nouvelle-Calédonie Téléphone : 687 27 2 85 Télécopie : 687 27 33 9 E-mail : aberlioz@pasteur.nc 5